YCBD - Rasio utang marang kapitalisasi buku cbdmd.com

Logo grafis cbdMD (YCBD)

The ratio of debt to book capitalization underscores the status of cbdMD, Inc. (YCBD) as a reputable supplier for athletes with high purification standards. This metric remains around 0.27, correlating with investments in R&D and extract purity verification. Current growth relies on online sales and retail while opportunities for global market expansion are being developed.

YCBD (cbdMD) riwayat Utang marang nilai buku saka 04.07.2022 nganti 27.10.2026
Barang utama cbdMD

Determining fundamental stability requires separating real solvency from short-term price fluctuations. This indicator measures the share of borrowed funds in total asset value to determine the level of financial leverage. Analyzing debt obligations relative to the balance sheet capital structure allows for an assessment of credit shock risk. For cbdMD, Inc. (YCBD), low leverage confirms stability during the implementation of eco-friendly packaging standards. Controlling the debt load guarantees the continued development of cannabidiol product manufacturing.

Pesaing cbdMD, Inc.

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik tonixpharma.com (TNXP)|China SXT Pharmaceuticals, Inc. - Utang-utang marang kapitalisasi buku|Utang marang nilai buku Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Utang-utang marang kapitalisasi buku|EXOZ - Rasio utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku oramed.com|ENTX (Entera Bio) - Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku HYFT|Utang marang nilai buku ABVC BioPharma Inc.|Utang-utang marang kapitalisasi buku Cumberland Pharma CPIX|Rasio utang marang nilai buku Quantum BioPharma Corp QNTM|Utang marang nilai buku FibroGen, Inc.|Rasio utang marang aset resik telomirpharma.com TELO|Utang-utang marang kapitalisasi buku RANI (Rani Therapeutics Inc)|SNYR: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku rallybio.com|Lexaria Bioscience Corp. (LEXX) - Rasio utang marang nilai buku|Utang-utang marang kapitalisasi buku PULM|Utang marang nilai buku Pheton (PTHL)|APM (Aptorum Group Limited) - Utang marang nilai buku|Utang-utang marang aset resik Lyra Therapeutics Inc. LYRA|IBO: Utang marang nilai buku|Utang-utang marang nilai buku TNF Pharmaceuticals Inc. TNFA|PRFX: Utang-utang marang kapitalisasi buku|CYTO - Utang marang nilai buku|Lipella Pharmaceuticals, Inc. (LIPO) - Utang-utang marang kapitalisasi buku|OptiNose Inc (OPTN) - Rasio utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Pieris (PIRS)|Rasio utang marang nilai buku PROC|PTPI - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku qlsyy.net (QLI)|Utang-utang marang kapitalisasi buku ACELYRIN|Rasio utang marang aset resik TFF Pharmaceuticals Inc. TFFP